NEW BRUNSWICK, N.J., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Myseum, Inc. (Nasdaq: MYSE) (“Myseum” or the “Company”), a privacy-first social media and technology innovator, today announced that it has received a notice of allowance from the U.S Patent and Trademark Office (USPTO) for application #18/487,726 titled “Secure Web RTC Real Time Communications Service for Audio and Video Streaming Communications.” This new international patent further strengthens Myseum’s growing intellectual property portfolio and glo ...

Kering - Statement Number of Shares and voting rights - 15.10.2025 KeringSociété anonyme with a share capital of €493,683,112Head office: 40, rue de Sèvres – 75007 PARIS552 075 020 RCS PARIS October 16, 2025 Monthly statement on the total number of shares and voting rights(articles L.233-8 of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (AMF – Autorité des Marchés Financiers) Date Total number ofshares Total number of voting rights theoreti ...

ROCKVILLE, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced its entry into a warrant inducement agreement with existing institutional investors of the Company for the immediate exercise of warrants to purchase up to 7,360,460 of common stock (the “Existing Warrants”) at a reduced exercise price of ...

NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- StepStone Real Estate (“SRE”), the real estate arm of StepStone Group (NASDAQ: STEP), a global private markets investment firm, today announced that it has finalized the size of its StepStone Real Estate Partners V (“SREP V”) GP-led secondaries program, with total commitments of $5.3 billion. In April 2025, SRE announced it had closed $4.5 billion in total commitments for the program, which included a commingled fund of $3.77 billion and discretionary co-investmen ...

Core Insights - Candel Therapeutics has appointed Dr. Bali Pulendran to its Research Advisory Board, enhancing its expertise in systems immunology and vaccinology as it advances its viral immunotherapy candidates [1][2][3] Company Overview - Candel Therapeutics is a clinical-stage biopharmaceutical company focused on developing multimodal viral immunotherapies to elicit systemic anti-tumor immune responses [4] - The company has established two clinical-stage platforms based on genetically modified adenovirus and herpes simplex virus (HSV) gene constructs [4] Product Development - Candel's lead product candidate, CAN-2409, has completed successful phase 2a clinical trials in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) [5] - A pivotal phase 3 clinical trial of CAN-2409 in localized prostate cancer is underway, conducted under a Special Protocol Assessment (SPA) with the FDA [5] - CAN-2409 has received Fast Track Designation from the FDA for multiple indications, including PDAC and stage III/IV NSCLC [5] - CAN-3110, the lead candidate from the HSV platform, is currently in a phase 1b clinical trial for recurrent high-grade glioma and has also received Fast Track and Orphan Drug Designations from the FDA [6] Research and Development - Dr. Pulendran's expertise is expected to provide valuable insights into the immune system's response to therapies, aiding in the advancement of CAN-2409 and CAN-3110 [2][3] - Candel's enLIGHTEN™ Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors [6]

Core Insights - NextCure, Inc. and Simcere Zaiming have initiated the dosing of the first patient in the U.S. for the Phase 1 trial of SIM0505, an antibody drug conjugate targeting advanced solid tumors [1][3] Company Overview - NextCure is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies, particularly for patients who do not respond to existing treatments [4] - Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group, is dedicated to creating groundbreaking therapies for cancer patients globally, with a strong R&D pipeline [5] Product Development - SIM0505 is designed as a novel antibody drug conjugate targeting cadherin-6 (CDH6) and includes a proprietary topoisomerase 1 inhibitor payload, aiming for broad anti-tumor activity and improved therapeutic potential [2] - The ongoing Phase 1 trial has expanded to include U.S. patients, with dose escalation currently progressing in China [2] Clinical Trial Progress - The first patient in the U.S. has been dosed at a mid-tier level where clinical responses have been observed, marking a significant milestone in the global development of SIM0505 [3][7] - The trial aims to accelerate the timeline for proof-of-concept data, expected in the first half of 2026 [7]

LONDON and MADRID, Oct. 16, 2025 (GLOBE NEWSWIRE) -- StepStone Real Estate (SRE), the real estate arm of StepStone Group (Nasdaq: STEP) and GREYKITE (GK), the independent European real estate investment firm, announce the planned recapitalization of Vitalia, Spain’s second largest care home owner-operator, through the agreement to acquire a majority interest in Vitalia from Vivaly Investments BV, a portfolio investment of CVC Fund VI and Portobello Capital Fund III, and the commitment of over €500 million ...

Core Viewpoint - Dime Community Bancshares, Inc. is set to release its earnings for the third quarter of 2025 on October 23, 2025, before the U.S. equity markets open, with a conference call scheduled for the same day to discuss financial performance [1]. Group 1 - The earnings announcement will occur before the market opens on October 23, 2025 [1]. - A conference call will be held at 8:00 a.m. (ET) on the same day, featuring remarks from the CEO, Stuart Lubow [1]. - There will be a question-and-answer session following the CEO's remarks during the conference call [1]. Group 2 - Participants can access the conference call via a webcast link or by registering in advance for telephone participation [2]. - Telephone participants will receive a confirmation email with details on how to join the call, including a unique PIN [2]. - It is recommended that participants dial in 10 minutes prior to the start time [2]. Group 3 - A replay of the conference call and webcast will be available on-demand for 12 months [3]. Group 4 - Dime Community Bancshares, Inc. is the holding company for Dime Community Bank, which has over $14 billion in assets and holds the number one deposit market share among community banks in Greater Long Island [4]. - The company focuses on community banking and has a significant presence in Kings, Queens, Nassau, and Suffolk counties [5].

Core Insights - Belite Bio Inc is a clinical-stage drug development company focused on novel therapeutics for degenerative retinal diseases with significant unmet medical needs [2] Group 1: Company Overview - Belite Bio is targeting diseases such as STGD1 and GA in advanced dry AMD, as well as specific metabolic diseases [2] - The lead candidate, Tinlarebant, is an oral therapy aimed at reducing bisretinoid toxin accumulation in the eye [2] - Tinlarebant is currently undergoing multiple clinical trials, including a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) for adolescent STGD1 subjects, and a Phase 3 study (PHOENIX) for subjects with GA [2] Group 2: Upcoming Events - The executive management team will participate in the Maxim Growth Summit on October 22, 2025 [1] - Interested parties can schedule one-on-one meetings with management through their Maxim representative [1]

Credit washing emerges as a growing concern as synthetic fraud and misrepresentation tactics evolveLAS VEGAS, Oct. 16, 2025 (GLOBE NEWSWIRE) -- New analysis from TransUnion (NYSE: TRU) released at this week’s Auto Finance Summit reveals that fraud-related charge-off losses in auto lending are not only significant—they are dramatically higher than those seen in other consumer credit product types. Synthetic identity fraud, which occurs when real and fake information are combined to create a new, fictitious i ...